Nephropathy Clinical Trial
Official title:
Effects of the SGLT2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-diabetic Subjects
SGLT-2 inhibitors belong to a new class of hypoglycemic drugs with the unique property of
decreasing blood glucose through an increase in glucosuria. These drugs inhibit the sodium
glucose transporter 2 (SGLT2) expressed at the luminal membrane of the proximal tubule.
SGLT-2 inhibition in type 2 diabetic subjects and in healthy volunteers shifts the threshold
for renal glucose excretion to lower levels. This effect is independent from insulin. The
inhibition of SGLT2 decreases HbA1C, systolic blood pressure and weight in diabetic subjects.
Recently, the EMPA-REG trial demonstrated a decrease in cardiovascular mortality and renal
endpoints in empagliflozin treated type 2 diabetic patients with established cardio-vascular
disease.
Because this novel hypoglycemic drug has unique and direct effects on renal tissue
metabolism, it is important to better examine its effects on the kidney. With this study, we
propose to explore the effects of empagliflozin on renal tissue oxygenation. Our hypothesis
is that SGLT-2 inhibition decreases renal cortical energy requirements with consequently an
increase in renal tissue oxygenation.
This study is a double-blind, randomized, placebo-controlled study that will examine the
acute and chronic renal effects of empagliflozin in healthy volunteers.
A total of 45 healthy volunteers will be included in the study: 15 normal weight, 15
overweight (BMI: 25-30kg/m2) and 15 obese (BMI>30kg/m2) non diabetic subjects (as determined
after an oral glucose tolerance test).
Empagliflozin 10mg vs placebo will be administered in a blinded fashion qd. The acute and
chronic renal response to empagliflozin will be assessed.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Recruiting |
NCT01448889 -
Normobaric Hyperoxygenation for Prevention of Contrast Induced Nephropathy
|
N/A | |
| Active, not recruiting |
NCT05026021 -
Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia
|
||
| Completed |
NCT02470247 -
Interest of Remote Ischemic Preconditioning for Prevention of Contrast Medium-induced Nephropathy in High Risk Patients
|
N/A | |
| Recruiting |
NCT05511779 -
Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation
|
Phase 2 | |
| Active, not recruiting |
NCT03584217 -
Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03620773 -
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
|
Phase 1/Phase 2 | |
| Completed |
NCT03618420 -
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
|
Phase 1/Phase 2 | |
| Completed |
NCT02575092 -
The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05839314 -
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
|
Phase 4 | |
| Completed |
NCT01638663 -
Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)
|
Phase 2 | |
| Completed |
NCT01208701 -
The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy
|
Phase 2 | |
| Completed |
NCT01213498 -
The Effects of Atorvastatin on the Nitric Oxide-system in Patients With Non-diabetic Nephropathy
|
Phase 2 | |
| Completed |
NCT01214746 -
The Effects of Atorvastatin on the Nitric Oxide-system in Healthy Young Man
|
Phase 2 | |
| Active, not recruiting |
NCT00655330 -
Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy
|
N/A | |
| Completed |
NCT00308347 -
A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)
|
Phase 3 | |
| Terminated |
NCT00579995 -
A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate
|
N/A | |
| Completed |
NCT05986474 -
Development of Synthetic Medical Data Generation Technology to Predict Postoperative Complications
|
||
| Recruiting |
NCT03886714 -
Screening for Fabry Disease in Renal Transplantation
|
||
| Recruiting |
NCT06325059 -
The Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases
|
N/A |